{"organizations": [], "uuid": "9896dbd91b7802c5167e5b004c71a991f7f305bd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-gsk-ceo-says-will-take-serious-loo/brief-gsk-ceo-says-will-take-serious-look-at-major-consumer-health-assets-idUSL9N15G04O", "country": "US", "domain_rank": 408, "title": "BRIEF-GSK CEO says will take serious look at major consumer health assets", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-07T20:49:00.000+02:00", "replies_count": 0, "uuid": "9896dbd91b7802c5167e5b004c71a991f7f305bd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-gsk-ceo-says-will-take-serious-loo/brief-gsk-ceo-says-will-take-serious-look-at-major-consumer-health-assets-idUSL9N15G04O", "ord_in_thread": 0, "title": "BRIEF-GSK CEO says will take serious look at major consumer health assets", "locations": [], "entities": {"persons": [{"name": "emma walmsley", "sentiment": "negative"}], "locations": [{"name": "uk", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "glaxosmithkline", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "none"}, {"name": "gsk", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 7 (Reuters) - Glaxosmithkline CEO Emma Walmsley tells reporters:\n* CEO SAYS OBVIOUSLY EXPECTING MORE COMPETITION IN HIV THIS YEAR\n* CEO SAYS FIRST PRIORITY IS PHARMA RESEARCH AND DEVELOPMENT, WHICH COULD INCLUDE EARLY-STAGE DRUG DEALS\n* CEO SAYS NEXT PRIORITY IS CONSUMER PUT FROM NOVARTIS, IF IT COMES\n* CEO SAYS NO COMMENT ON PFIZER CONSUMER HEALTHCARE AUCTION BUT SHOULD EXPECT GSK TO TAKE SERIOUS LOOK AT MAJOR CONSUMER ASSETS\n* CEO SAYS BIG CONSUMER HEALTH DEAL ‘NOT A NEED TO DO’\n* CEO SAYS BELIEVES SHINGRIX WILL BE BIGGEST VACCINE FOR GSK OVER MEDIUM TO LONG TERM\n* CEO SAYS ‘WE KNOW DIVIDEND MATTERS TO OUR SHAREHOLDERS’\n* CEO SAYS MOST IMPORTANT THING ON BREXIT IS TO GET A TRANSITION PERIOD OF AT LEAST 2 YEARS, SECURED BY APRIL 2018\n* CEO SAYS ON BREXIT INDUSTRY NEEDS MUTUAL RECOGNITION, CLOSE WORK WITH EMA, MINIMAL TRADE FRICTION, CONTINUED RESEARCH AND DEVELOPMENT COLLABORATION WITH EU Further company coverage: (Reporting by UK bureau)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-07T20:49:00.000+02:00", "crawled": "2018-02-09T06:10:33.003+02:00", "highlightTitle": ""}